Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 37 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

32%

12 trials in Phase 3/4

Results Transparency

17%

5 of 30 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

N/A
12(40.0%)
Phase 4
8(26.7%)
Phase 2
6(20.0%)
Phase 3
4(13.3%)
30Total
N/A(12)
Phase 4(8)
Phase 2(6)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials
NCT03031912Phase 2Completed

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Role: collaborator

NCT05951751Not ApplicableRecruiting

The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)

Role: collaborator

NCT05730569Recruiting

Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso

Role: collaborator

NCT04029454Not ApplicableCompleted

Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule

Role: collaborator

NCT05009823Completed

Dietary Rehabilitation in Severely Acutely Malnourished Children

Role: collaborator

NCT05020847Not ApplicableCompleted

Effectiveness of Alternative Diets During the Stabilization Phase on Children With Complicated SAM

Role: collaborator

NCT05015257Not ApplicableCompleted

Effectiveness of Four Transition Dietary Regimens in the Hospital Management of Children With Kwashiorkor.

Role: collaborator

NCT04920838Phase 2Unknown

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Role: collaborator

NCT03870438Phase 3Completed

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention

Role: collaborator

NCT03869944Phase 2Unknown

Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV

Role: collaborator

NCT02564523Phase 2Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Role: collaborator

NCT04136405Unknown

Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso

Role: collaborator

NCT04445441Completed

An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso

Role: lead

NCT02509481Phase 2Completed

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Role: collaborator

NCT02435524Not ApplicableCompleted

Alive & Thrive Evaluation in Burkina Faso

Role: collaborator

NCT02341469Not ApplicableCompleted

A Trial of an Integrated E-diagnosis Assessment to Improve the Management of Childhood Illnesses in Burkina Faso

Role: collaborator

NCT02237027Phase 4Completed

Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin

Role: collaborator

NCT01747369Unknown

Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013

Role: collaborator

NCT01941264Not ApplicableCompleted

Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial

Role: collaborator

NCT00852423Phase 3Completed

Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

Role: collaborator